Legacy Pharma

Swiss pharma giant Roche (SWX: ROG) has transferred US-based InterMune, Inc., acquired for USD 8 billion in 2014, and the intellectual property (IP) rights to Esbriet (pirfenidone) in the US to Legacy Pharma Inc. SEZC. Financial terms were undisclosed. FinancialsEsbriet, an idiopathic pulmonary fibrosis (IPF) drug, saw peak sales of…